Clinical trials: Panic Disorder
Panic Disorder
Study Evaluating Venlafaxine ER in Adults With Panic Disorder
The primary objective of this study is to determine the efficacy, safety, and tolerability of a flexible dose of venlafaxine extended-release (ER) capsules administered for 10 weeks in the treatment of adult outpatients with…
- Trial name
- NCT00038896
- Testing
- Venlafaxine ER
- Volunteers
- 343 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Panic Disorder, Mental Illness
Efficacy and Safety of HB-1 for Panic Disorder
The purpose of this study is to determine the safety and efficacy of HB-1, versus placebo and two monotherapies, in male and female adult patients aged 18 to 65 years, inclusive, with Panic Disorder.
- Trial name
- NCT06483789
- Testing
- HB-1, Telmisartan Only Product in Oral Dose Form, Verapamil Only Product in Oral Dose Form
- Where
- 19 sites in Australia
- Volunteers
- 170 people
- Sponsor
- HB BioTech, LLC
Panic Disorder
A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder
To evaluate the efficacy and safety of sertraline compared to paroxetine in patients with panic disorder.
- Trial name
- NCT00677352
- Testing
- sertraline, Paroxetine
- Where
- 22 sites in Japan
- Volunteers
- 321 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Panic Disorder
Safety and Efficacy of HB-1 for Panic Disorder
The purpose of this study is to determine the safety and efficacy of potential new treatment called "HB-1" versus placebo in male and female adult patients aged 18 to 60 years, inclusive, with panic disorder.
- Trial name
- NCT05071430
- Testing
- HB-01
- Where
- 10 sites in United States
- Volunteers
- 86 people
- Sponsor
- HB BioTech, LLC
Panic Disorder
A Trial of the Effect of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy Subjects
The purpose of this study is to determine anxiolytic effect of multiple doses of CVL-865 using an experimental medicine model of carbon dioxide (CO2) inhalation in healthy volunteers.
- Trial name
- NCT04592536
- Testing
- CVL-865 High dose, Alprazolam 1mg XR, CVL-865 low dose
- Where
- Netherlands
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Cerevel Therapeutics, LLC
Panic Disorder
Org 25935 Versus Placebo as Augmentation to Cognitive-behavioral Therapy to Treat Panic Disorder (P05705)
The purpose of this study is to evaluate the effectiveness of Org 25935 vs. placebo given in combination with cognitive-behavioral therapy (CBT) to reduce the symptoms of panic disorder.
- Trial name
- NCT00725725
- Testing
- Cognitive-behavioral therapy, Org 25935
- Volunteers
- 46 people
- Sponsor
- Merck Sharp & Dohme LLC
Panic Disorder
Study Evaluating Venlafaxine ER in Patients With Panic Disorder
The primary objective is to determine the efficacy, safety, and tolerability of venlafaxine extended release (ER) capsules in the treatment of outpatients with panic disorder (PD) in comparison to those of placebo.
- Trial name
- NCT00044772
- Testing
- Venlafaxine ER
- Volunteers
- 653 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Panic Disorder
A Study to Evaluate the Use of Extended Release Alprazolam in the Treatment of Adolescents With Panic Disorder
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics of alprazolam extended release (XR) for the treatment of adolescents with panic disorder
- Trial name
- NCT00635531
- Testing
- alprazolam XR
- Where
- 18 sites in United States
- Volunteers
- 16 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Panic Disorder
Using the Canary Breathing System for Panic Disorder Patients
The purpose of this study is to test the effectiveness of the Canary Breathing System (CBS) in treating the symptoms of panic disorder.
- Trial name
- NCT01955954
- Testing
- Canary Breathing System
- Where
- 4 sites in United States
- Volunteers
- 69 people
- Sponsor
- Palo Alto Health Sciences, Inc.
Healthy Subjects
An Bioequivalence Study Of Xanax Extended Release Tablets From Two Different Manufacturing Sites
Study to evaluate if Xanax sustained release tablets manufactured at two different sites provide similar drug levels in the blood.
- Trial name
- NCT01330472
- Testing
- Xanax XR tablets 3 mg (sourced from Caugus), Xanax XR tablets 3 mg (sourced from Barceloneta)
- Where
- Singapore
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Panic Disorder
Xenon Inhalation for Treatment of Panic Disorder
This study is a double-blind, randomized, placebo-controlled, clinical trial in parallel groups in patients with panic disorder.
- Trial name
- NCT04432155
- Testing
- Xenon
- Volunteers
- 200 people
- Sponsor
- Nobilis Therapeutics Inc.
Post-traumatic Stress Disorder (PTSD)
A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline
A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline
- Trial name
- NCT05189977
- Testing
- Propranolol, Prazosin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Panic Disorder
A Study to Assess the Long-term Use of Alprazolam Extended Release (XL) in the Treatment of Adolescents With Panic Disorder
The purpose of this study is to evaluate the long-term (6-month) efficacy, safety, and tolerability of alprazolam XR in adolescents with panic disorder.
- Trial name
- NCT00635076
- Testing
- alprazolam XR
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Panic Disorders
Study Comparing Venlafaxine vs. Paroxetine in Panic Disorder
The purpose of this pilot study is to evaluate the improvement in social function following therapy with venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paroxetine.
- Trial name
- NCT00195598
- Testing
- VENLAFAXINE, Paroxetine
- Where
- 4 sites in Brazil
- Volunteers
- 70 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Panic Disorder
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder
The purpose of this trial is to measure the efficacy, safety, and tolerability of darigabat (25 milligrams [mg] twice daily [BID]) compared with placebo in participants with panic disorder.
- Trial name
- NCT05941442
- Testing
- Darigabat
- Where
- 31 sites in United States
- Volunteers
- 80 people
- Sponsor
- AbbVie
Panic Disorder
Special Investigation Of J Zoloft For Panic Disorder Patients
The objective of this surveillance is to collect information for panic disorder patients about 1) adverse drug reactions not expected from the LPD (unknown adverse drug reactions), 2) the incidence of adverse drug reactions in…
- Trial name
- NCT00605917
- Testing
- Sertraline hydrochloride
- Volunteers
- 997 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Anxiety, Fear
A Randomized Controlled Test of the Effects of CHI-554 on Fear.
This is a randomized, double-blind, placebo-controlled phase 2b clinical trial examining the effects of CHI-554 (CBD) on Fear (F-01)
- Conditions
- Anxiety, Fear, Panic
- Trial name
- NCT04577612
- Testing
- CHI-554
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Canopy Growth Corporation
Panic Disorder
Special Drug Use Investigation for PAXIL Tablet (Investigation in Case of Administered From 20mg/Day)
The objective of this survey was to understand the safety and efficacy of PAXIL tablets ("PAXIL", hereinafter) when it was started at 20 mg/day in subjects with depression or in a depressed state.
- Trial name
- NCT01371474
- Testing
- Paroxetine
- Volunteers
- 1,483 people
- Sponsor
- GlaxoSmithKline
Panic Disorder
Special Drug Use Investigation for PAXIL Tablet (Pediatric Panic Disorder)
The objectives of this survey was to retrospectively collect and evaluate the information on the efficacy and safety of PAXIL tablets ("PAXIL", hereinafter) in pediatric subjects (aged under 18) with panic disorder under…
- Trial name
- NCT01376128
- Testing
- Paroxetine
- Volunteers
- 96 people
- Sponsor
- GlaxoSmithKline
Panic Disorder
ELB139 Given Orally to Patients With Concurrent Panic Disorder, Challenged by CO2 Inhalation After a Single Dose and One Week of Treatment
This study is designed to investigate if 600 mg ELB139 given orally t.i.d. to patients suffering from panic disorder is effective in reducing anxiety evoked by inhalation of 35% CO2 measured by a visual analogue scale after the…
- Trial name
- NCT00322803
- Testing
- ELB139
- Where
- 3 sites in Germany, Netherlands
- Volunteers
- 24 people
- Sponsor
- elbion AG